Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: High frequency of germline TP53 mutations in a prospective adult-onset sarcoma cohort
Author: Mitchell, G.
Ballinger, M.
Wong, S.
Hewitt, C.
James, P.
Young, M.
Cipponi, A.
Pang, T.
Goode, D.
Dobrovic, A.
Thomas, D.
Porceddu, S.
Gattas, M.
Neuhaus, S.
Suthers, G.
Tattersall, M.
Tucker, K.
Lewis, C.
Carey-Smith, R.
Citation: PLoS One, 2013; 8(7):e69026-1-e69026-7
Publisher: Public Library of Science
Issue Date: 2013
ISSN: 1932-6203
Editor: Toft, M.
Statement of
Gillian Mitchell, Mandy L. Ballinger, Stephen Wong, Chelsee Hewitt, Paul James, Mary- Anne Young, Arcadi Cipponi, Tiffany Pang, David L. Goode, Alex Dobrovic, David M. Thomas, on behalf of the International Sarcoma Kindred Study
Abstract: Sarcomas are a key feature of Li-Fraumeni and related syndromes (LFS/LFL), associated with germline TP53 mutations. Current penetrance estimates for TP53 mutations are subject to significant ascertainment bias. The International Sarcoma Kindred Study is a clinic-based, prospective cohort of adult-onset sarcoma cases, without regard to family history. The entire cohort was screened for mutations in TP53 using high-resolution melting analysis and Sanger sequencing, and multiplex-ligation-dependent probe amplification and targeted massively parallel sequencing for copy number changes. Pathogenic TP53 mutations were detected in blood DNA of 20/559 sarcoma probands (3.6%); 17 were germline and 3 appeared to be somatically acquired. Of the germline carriers, one appeared to be mosaic, detectable in the tumor and blood, but not epithelial tissues. Germline mutation carriers were more likely to have multiple cancers (47% vs 15% for non-carriers, P = 3.0×10(-3)), and earlier cancer onset (33 vs 48 years, P = 1.19×10(-3)). The median survival of mutation carriers following first cancer diagnosis was not significantly different from non-carriers. Only 10/17 (59%) pedigrees met classical or Chompret criteria for LFS. In summary, germline TP53 mutations are not rare in adult patients with sarcoma, with implications for screening, surveillance, treatment and genetic counselling of carriers and family members.
Keywords: International Sarcoma Kindred Study
Cohort Studies
Prospective Studies
Age of Onset
Base Sequence
Germ-Line Mutation
Middle Aged
Tumor Suppressor Protein p53
Kaplan-Meier Estimate
Rights: © 2013 Mitchell et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
DOI: 10.1371/journal.pone.0069026
Grant ID:
Appears in Collections:Aurora harvest 7
Medicine publications

Files in This Item:
File Description SizeFormat 
hdl_94840.pdfPublished version444.15 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.